|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.37 USD | -1.11% |
|
+13.78% | +37.16% |
| 02-20 | UBS Adjusts Price Target on 10x Genomics to $20 From $14, Maintains Neutral Rating | MT |
| 02-12 | 10x Genomics, Inc., Q4 2025 Earnings Call, Feb 12, 2026 |
| Capitalization | 2.86B 2.46B 2.23B 2.14B 3.91B 263B 4.05B 26.2B 10.49B 126B 10.73B 10.5B 449B | P/E ratio 2026 * |
-23.1x | P/E ratio 2027 * | -29.3x |
|---|---|---|---|---|---|
| Enterprise value | 2.37B 2.04B 1.85B 1.78B 3.24B 219B 3.36B 21.76B 8.71B 104B 8.91B 8.72B 373B | EV / Sales 2026 * |
3.87x | EV / Sales 2027 * | 3.55x |
| Free-Float |
85.02% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: 10x Genomics, Inc.
| 1 day | -1.11% | ||
| 1 week | +13.78% | ||
| Current month | -2.95% | ||
| 1 month | +17.37% | ||
| 3 months | +23.25% | ||
| 6 months | +64.85% | ||
| Current year | +37.16% |
| 1 week | 21.21 |  | 23.3 |
| 1 month | 17.26 | | 23.3 |
| Current year | 16.22 | | 23.56 |
| 1 year | 6.78 | | 23.56 |
| 3 years | 6.78 | | 63.57 |
| 5 years | 6.78 | | 208.99 |
| 10 years | 6.78 | | 208.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Serge Saxonov
CEO | Chief Executive Officer | 49 | 01/07/2012 |
Ben Hindson
PSD | President | 51 | 30/09/2012 |
Adam Taich
DFI | Director of Finance/CFO | 51 | 11/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Ben Hindson
BRD | Director/Board Member | 51 | 01/07/2012 |
Serge Saxonov
BRD | Director/Board Member | 49 | 01/07/2012 |
John Stuelpnagel
CHM | Chairman | 68 | 31/07/2013 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.11% | +13.78% | +112.64% | -56.14% | 2.86B | |
| -2.60% | -0.88% | -17.20% | +2.50% | 13.47B | |
| -0.30% | -2.36% | +124.25% | +189.96% | 12.2B | |
| +0.17% | +0.21% | -14.46% | -11.86% | 5.96B | |
| +2.48% | +8.47% | - | - | 5.61B | |
| -1.27% | +2.80% | -20.71% | +6.72% | 5.03B | |
| -0.69% | -0.60% | -29.70% | -38.42% | 4.38B | |
| +0.97% | +13.54% | +21.72% | +5.11% | 3.1B | |
| -2.13% | -5.16% | -16.83% | -45.07% | 2.86B | |
| +3.93% | +4.67% | +30.76% | +52.75% | 1.84B | |
| Average | -0.05% | +4.24% | +21.16% | +11.73% | 5.73B | |
| Weighted average by Cap. | -0.56% | +2.92% | +26.34% | +38.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 613M 527M 479M 459M 838M 56.54B 868M 5.62B 2.25B 26.96B 2.3B 2.25B 96.3B | 658M 566M 513M 492M 899M 60.64B 931M 6.03B 2.41B 28.92B 2.47B 2.42B 103B |
| Net income | -121M -104M -94.76M -90.88M -166M -11.19B -172M -1.11B -446M -5.34B -456M -446M -19.07B | -96.23M -82.75M -75.09M -72.02M -132M -8.87B -136M -882M -353M -4.23B -361M -353M -15.11B |
| Net Debt | -484M -416M -377M -362M -661M -44.6B -685M -4.43B -1.78B -21.27B -1.82B -1.78B -75.96B | -526M -452M -410M -393M -718M -48.45B -744M -4.82B -1.93B -23.1B -1.97B -1.93B -82.52B |
Employees
1,178
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/03/26 | 22.37 $ | -1.11% | 1,974,472 |
| 03/03/26 | 22.62 $ | -2.25% | 2,435,523 |
| 02/03/26 | 23.14 $ | +0.39% | 3,050,768 |
| 27/02/26 | 23.05 $ | +4.16% | 3,756,888 |
| 26/02/26 | 22.13 $ | +12.56% | 3,713,734 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
22.37USD
Average target price
20.14USD
Spread / Average Target
-9.96%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TXG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition